Axsome Therapeutics, which is developing an oral formulation of an existing therapy for pain and osteoarthritis, filed on Tuesday with the SEC to raise up to $58 million in an initial public offering.
The company cites 2015 IPOs Carbylan Therapeutics (CBYL) and Flexion Therapeutics (FLXN) as potential competitors.
Help employers find you! Check out all the jobs and post your resume.
